Wednesday, March 13, 2013
With Ovarian Cancer, Better Outcome Tied to Guideline Adherence - MPR
With Ovarian Cancer, Better Outcome Tied to Guideline Adherence - MPR
"Robert E. Bristow, MD, from University of California Irvine Medical Center, and colleagues identified 13,321 consecutive patients from the California Cancer Registry diagnosed with epithelial ovarian cancer (Jan. 1, 1999–Dec. 31, 2006) undergoing a minimum surgical procedure of oophorectomy. Stage-appropriate surgical procedures and recommended chemotherapy was the definition of adherence to NCCN guideline care.
The researchers found that, overall, 37.2% of patients received NCCN guideline-adherent care. Nearly 19% of cases were seen at high-volume hospitals (≥20 cases/year) and 16.4% of surgeries were performed by high-volume surgeons (≥10 cases/year).
Editorial: Circulating Tumor DNA — Ready for Prime Time? — NEJM
Blogger's Note: this editorial references a breast cancer study/CTC
Circulating Tumor DNA — Ready for Prime Time? — NEJM
" In summary, the new study provides proof of the concept that circulating tumor DNA represents a sensitive biomarker of tumor burden. Demonstration that the method can be used to take better care of patients with metastatic breast or other cancers in a cost-effective manner awaits further studies, which are clearly warranted."
paywalled: (theory) The relationship between tumor size and stage in early versus advanced ovarian cancer
Abstract
Ovarian cancer has a different prognosis between early (I and II) and advanced stage (III and IV). The mechanism of disease progression is unknown, but patients with advanced disease may have a higher propensity for seeding of the abdominal cavity early in the disease process than those with early stage. Theoretically if this is so, then patients with advanced stage should have smaller sized tumors than patients with early stage.
numerous research articles: ovarian cancer search
Scholar Alert: [ intitle:"ovarian cancer" ]; Articles excluding patents
A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
DC Marchion, E Bicaku, Y Xiong, NB Zgheib… - Oncology reports, 2013
Elevated serum levels of hepatocyte growth factor (HGF) and high tumor expression of c-Met
are both indicators of poor overall survival from ovarian cancer (OVCA). In the present study,
we evaluated the role of the HGF signaling pathway in OVCA cell line chemoresistance ...
are both indicators of poor overall survival from ovarian cancer (OVCA). In the present study,
we evaluated the role of the HGF signaling pathway in OVCA cell line chemoresistance ...
Mirk/dyrk1B Kinase in Ovarian Cancer
E Friedman - International Journal of Molecular Sciences, 2013
Abstract: Mirk/dyrk1B kinase is expressed in about 75% of resected human ovarian cancers
and in most ovarian cancer cell lines with amplification in the OVCAR3 line. Mirk (minibrain-
related kinase) is a member of the Minibrain/dyrk family of related serine/threonine ...
and in most ovarian cancer cell lines with amplification in the OVCAR3 line. Mirk (minibrain-
related kinase) is a member of the Minibrain/dyrk family of related serine/threonine ...
The incidence of PALB2 c. 3113G> A in women with a strong family history of breast and ovarian cancer attending familial cancer centres in Australia.
ZL Teo, SD Sawyer, PA James, G Mitchell, AH Trainer… - Familial cancer, 2013
The familial aggregation of breast cancer has been well-described with approximately 25%
of breast cancers attributable to inherited mutations in currently known breast cancer
susceptibility genes. PALB2 c. 3113G> A (p. Trp1038*) is a protein-truncating mutation ...
of breast cancers attributable to inherited mutations in currently known breast cancer
susceptibility genes. PALB2 c. 3113G> A (p. Trp1038*) is a protein-truncating mutation ...
Immune escape of AKT overexpressing ovarian cancer cells.
JC Hahne, SR Meyer, S Gambaryan, U Walter, J Dietl… - International journal of …, 2013
Platinum-resistance is the most crucial problem for treatment of ovarian cancer. There is a
clinical need for new treatment strategies which overcome platinum resistance. As survival is
strongly influenced by immunological parameters, immunotherapeutic strategies appear ...
clinical need for new treatment strategies which overcome platinum resistance. As survival is
strongly influenced by immunological parameters, immunotherapeutic strategies appear ...
Folate-Conjugation to Polymeric Micelles via Boronic Acid Ester to Deliver Platinum Drugs to Ovarian Cancer Cell lines.
W Scarano, HT Duong, H Lu, PL De Souza… - Biomacromolecules, 2013
Abstract In this study, a novel technique was used for the reversible attachment of folic acid
on the surface of polymeric micelles for a tumor-specific drug delivery system. The reversible
conjugation is based on the interaction between phenylboronic acid (PBA) and dopamine ...
on the surface of polymeric micelles for a tumor-specific drug delivery system. The reversible
conjugation is based on the interaction between phenylboronic acid (PBA) and dopamine ...
[HTML] Tumor Stress-Induced Phosphoprotein1 (STIP1) as a Prognostic Biomarker in Ovarian Cancer
A Chao, CH Lai, CL Tsai, S Hsueh, C Hsueh, CY Lin… - PloS one, 2013
Abstract Stress-induced phosphoprotein 1 (STIP1) has been recently identified as a
released biomarker in human ovarian cancer. In addition, STIP1 secreted by human ovarian
cancer cells has been shown to promote tumor cell proliferation by binding to ALK2 ( ...
released biomarker in human ovarian cancer. In addition, STIP1 secreted by human ovarian
cancer cells has been shown to promote tumor cell proliferation by binding to ALK2 ( ...
The relationship between tumor size and stage in early versus advanced ovarian cancer
LE Horvath, T Werner, K Boucher, K Jones - Medical Hypotheses, 2013
Background Ovarian cancer has a different prognosis between early (I and II) and advanced
stage (III and IV). The mechanism of disease progression is unknown, but patients with
advanced disease may have a higher propensity for seeding of the abdominal cavity early ...
stage (III and IV). The mechanism of disease progression is unknown, but patients with
advanced disease may have a higher propensity for seeding of the abdominal cavity early ...
Icb-1 gene counteracts growth of ovarian cancer cell lines
O Treeck, S Schüler, J Häring, M Skrzypczak, C Lattrich… - Cancer Letters, 2013
Abstract Human gene icb-1 has been originally identified to be involved in differentiation
processes of cancer cells. To examine the function of icb-1 in ovarian cancer, we knocked
down its expression in three ovarian cancer cell lines and performed microarray-based ...
processes of cancer cells. To examine the function of icb-1 in ovarian cancer, we knocked
down its expression in three ovarian cancer cell lines and performed microarray-based ...
Effects of Sodium Valproate on the Growth of Human Ovarian Cancer Cell Line HO8910.
HC Yan, J Zhang - Asian Pacific journal of cancer prevention: APJCP, 2012
To explore a possible new treatment for human ovarian cancer, we studied the effects of
sodium valproate on the growth of the HO8910 human cell line. HO8910 cells were cultured
in vitro and treated with different concentrations of sodium valproate. Cell proliferation, cell ...
sodium valproate on the growth of the HO8910 human cell line. HO8910 cells were cultured
in vitro and treated with different concentrations of sodium valproate. Cell proliferation, cell ...
Identification of Cisplatin-Resistance Associated Genes through Proteomic Analysis of Human Ovarian Cancer Cells and a Cisplatin-resistant Subline.
J Zhou, YH Wei, MY Liao, Y Xiong, JL Li, HB Cai - Asian Pacific journal of cancer …, 2012
Chemoresistance to cancer therapy is a major obstacle to the effective treatment of human
cancers with cisplatin (DDP), but the mechanisms of cisplatin-resistance are not clear. In this
study, we established a cisplatin-resistant human ovarian cancer cell line (COC1/DDP) ...
cancers with cisplatin (DDP), but the mechanisms of cisplatin-resistance are not clear. In this
study, we established a cisplatin-resistant human ovarian cancer cell line (COC1/DDP) ...
Induction of apoptosis of ovarian cancer cells and influence on Fas-mediated apoptosis pathway by nanosecond pulsed electric fields].
R Xia, J Tang, X Zhao, F Guo, J Wang, C Yao - Sheng wu yi xue gong cheng xue za …, 2012
This paper is to investigate the apoptosis effect of ovarian cancer SKOV3 cells induced by
nanosecond plused electric fileds (nsPEFs) and to study its influence on Fas-mediated
apoptosis. SKOV3 cell were exposed to the 45kV/cm of field intensity, 30 pulses, and 50ns ...
nanosecond plused electric fileds (nsPEFs) and to study its influence on Fas-mediated
apoptosis. SKOV3 cell were exposed to the 45kV/cm of field intensity, 30 pulses, and 50ns ...
Prognosis is deteriorating for upper tract urothelial cancer
Blogger's Note/Opinion: while this study is specific to England, there are some key observations which would be applicable elsewhere; one item of key interest and not specific to UTUC is minimally invasive surgery which some recent research indicates a less than favourable surgical mechanism (for a variety of reasons); there are blog posts on this site regarding the issue; note also that imagine of the ureters is often difficult (CT urogram is the favored imaging for suspicion of ureteral malignancy); this research should be of interest to Lynch Syndrome patients including ovarian cancer patients (and others) with widespread disease (re: extension (seeding) of malignancy to bladder....)
Prognosis is deteriorating for upper tract urothelial cancer: data for England 1985–2010 - Eylert - 2013 - BJU International - Wiley Online Library
Objective
- To ascertain current trends in the incidence and mortality rates for upper tract urothelial cancer (UTUC) and identify any relationship with age, stage at presentation, social deprivation and treatment method.
Tuesday, March 12, 2013
Medicare Spending Not Linked to Advanced Cancer Survival
Medscape
There is substantial regional variation in Medicare spending for patients with advanced cancer, but there is no consistent association between mean regional spending and disease survival.....
Medscape Medical News
(social determinents of health) Are health inequalities really not the smallest in the Nordic welfare states? A comparison of mortality inequality in 37 countries
Blogger's Note: this is not specific to ovarian/cancer but relates to SDOH (eg. is SDOH (ie: poverty) all that matters or is it part of the problem?
open access
(Ottawa) Is race a prognostic factor in determining ovarian cancer survival outcomes? The answer is not just black and white
Abstract: Journal of Epidemiology & Community Health
Conclusions Despite statistically significant evidence demonstrating that AA women experience worse survival outcomes in ovarian cancer than WA women, it would be premature to conclude that race is the only prognostic factor. Race is a social determinant that influences other variables that affect treatment and survival of ovarian cancer, such as education, occupation, socioeconomic status and access to healthcare. Therefore, future studies are required to further assess the complicated relationship between survival outcomes and race.
Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial
Abstract
Purpose To determine whether abagovomab maintenance therapy prolongs recurrence-free (RFS) and overall survival (OS) in patients
with ovarian cancer in first clinical remission.
abstract: Phase II Study of Carboplatin and Weekly Irinotecan Combination Chemotherapy in Recurrent Ovarian Cancer
Abstract
Background: A multicenter phase II trial
was conducted to evaluate the efficacy and toxicity of irinotecan plus
carboplatin
chemotherapy in patients with epithelial ovarian
cancer (EOC).
Patients and Methods: Patients with either radiologically-
or serologically-recurrent EOC were administered
intravenous irinotecan (60 mg/m2; days 1 and 8) and
carboplatin area under the curve of 5 mg/ml/min (day 1), repeated every
21 days. The primary end-point
was response rate (RR), while the secondary
end-points were adverse events and progression-free survival (PFS).
A Population-based Series of Ovarian Carcinosarcomas with Long-term Follow-up
Abstract
Aim: The aim of the present study was to
evaluate a consecutive series of ovarian carcinosarcomas with regard to
prognosis,
treatment and prognostic factors.
Was Heart Disease the Mummies' Real Curse? - MedicineNet
Blogger's Note: of interest to all as cancer has been found (breast, ovarian...) in Egyptian times as well; while incidences of health-related diseases is not new it does have implications to today's settings, as indicated by the article (worth reading)
Was Heart Disease the Mummies' Real Curse? - MedicineNet
Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: Relationships with depression, fatigue, and disability
Abstract
Highlight
►
Patients undergoing primary treatment for ovarian cancer experience
reductions in inflammation and improvements in fatigue, vegetative
depression and disability.
Do Survivorship Care Plans Impact Patients’ Evaluations of Care? A Randomized Evaluation with Gynecologic Oncology Patients
Abstract
Highlights
►
Oncologists were randomized to provide/not provide survivorship care
plans (SCPs) to gynecologic oncology patients at follow-up.
► Patients rated quality of care similarly regardless if they had/had not received an SCP during recent follow-up visit.
► The need remains for further evaluations of SCPs if they are to be vehicles for improving patient-reported outcomes.
► Patients rated quality of care similarly regardless if they had/had not received an SCP during recent follow-up visit.
► The need remains for further evaluations of SCPs if they are to be vehicles for improving patient-reported outcomes.
Objective
Despite
recommendations from the Institute of Medicine regarding survivorship
care plan (SCP) delivery to cancer patients, there have been few health
service outcome evaluations thus far.
Subscribe to:
Posts
(
Atom
)
